Anaphylaxis: Acute Management

Key Points

• Immediate IM epinephrine in the mid‑anterolateral thigh is first‑line.
• support airway/breathing/circulation, identify trigger, and arrange observation with autoinjector and action plan at discharge.
• Adult IM: 0.3–0.5 mg (1 mg/mL) lateral thigh.
• Pediatric IM: 0.01 mg/kg up to 0.3–0.5 mg.
• Infusion: 1–10 mcg/min titrate to MAP.
• Do not delay epinephrine for IV access or antihistamines.

Algorithm

1. Determine whether the presentation is an acute allergic emergency, chronic inflammatory/allergic disease, drug reaction, or immune-deficiency phenotype.
2. Treat airway, breathing, circulation, or severe organ involvement immediately before confirmatory allergy/immunology testing.
3. Choose mechanism-specific testing: sensitization testing, challenge, biopsy, pulmonary phenotyping, or immune evaluation as appropriate.
4. Start first-line mechanism-directed therapy and remove clinically relevant triggers or culprit drugs.
5. Measure control objectively and escalate to immunotherapy, biologic/systemic therapy, immunoglobulin replacement, or specialist care only when criteria are met.
6. Apply the topic-specific branch 'Adult IM' when appropriate: 0.3–0.5 mg (1 mg/mL) lateral thigh.
7. Apply the topic-specific branch 'Pediatric IM' when appropriate: 0.01 mg/kg up to 0.3–0.5 mg.
8. Implementation check: Do not delay epinephrine for IV access or antihistamines.

Clinical Synopsis & Reasoning

Immediate IM epinephrine in the mid‑anterolateral thigh is first‑line; support airway/breathing/circulation, identify trigger, and arrange observation with autoinjector and action plan at discharge.

The central clinical task in Anaphylaxis: Acute Management is to identify the immune mechanism and determine whether the patient has an immediate airway/circulatory emergency, a chronic inflammatory phenotype requiring step-up control, or an immune deficiency that changes infection prevention. History should define timing, reproducibility, exposure, medication relationship, morphology, organ systems involved, previous reactions, infection pattern, atopic comorbidity, and treatment response. Mechanism matters because IgE-mediated disease, bradykinin angioedema, delayed T-cell reactions, eosinophilic disease, and antibody deficiency have very different tests and therapies.

Immediate escalation is required for anaphylaxis, progressive tongue or laryngeal edema, severe bronchospasm, shock, extensive epidermal detachment, severe mucosal disease, rapidly evolving organ injury, or serious infection in a patient with suspected immune deficiency. Stabilization takes priority over confirmatory testing. Epinephrine is first-line for anaphylaxis; it should not be delayed for laboratory confirmation, and antihistamines do not substitute for treatment of airway or circulatory compromise.

For nonemergent disease, distinguish sensitization from clinically relevant disease. A positive skin or serum IgE result demonstrates sensitization, not necessarily symptomatic allergy. Patch testing evaluates delayed contact hypersensitivity rather than immediate IgE reactions. Immunoglobulin levels and vaccine responses are interpreted in the context of infection phenotype and secondary causes. In eosinophilic and Type 2 disorders, biomarkers can help phenotype disease but do not replace the clinical syndrome.

Testing should be targeted to the question. Use supervised challenge when it is the safest and most definitive way to resolve uncertainty, but avoid challenges in patients with contraindicating severe reaction phenotypes. Use endoscopy/biopsy when tissue inflammation defines the disease. Use pulmonary function and Type 2 biomarkers to phenotype difficult asthma. Use quantitative immunoglobulins, cell counts, vaccine responses, and secondary-cause testing when recurrent infection suggests immune deficiency.

Topic-specific decision branches help convert mechanism into management. When the relevant branch is Adult IM, the practical implication is 0.3–0.5 mg (1 mg/mL) lateral thigh. When the relevant branch is Pediatric IM, the practical implication is 0.01 mg/kg up to 0.3–0.5 mg. When the relevant branch is Infusion, the practical implication is 1–10 mcg/min titrate to MAP. When the relevant branch is β‑blocker patient, the practical implication is Add glucagon 1–2 mg IV. When the relevant branch is Autoinjectors, the practical implication is 0.1/0.15/0.3 mg strengths. A practical implementation point from the source article is: Do not delay epinephrine for IV access or antihistamines. Provide trigger avoidance counseling and school/work plans. These branches should answer whether the patient needs acute rescue, trigger avoidance, a supervised challenge, immunotherapy, escalation to a biologic/systemic agent, immunoglobulin replacement, or specialty follow-up.

Long-term control should be measured with objective outcomes: reaction frequency, symptom-control scores, exacerbations, steroid exposure, food or medication tolerance, infection burden, lung function, histologic response, or quality of life depending on the condition. A treatment that does not improve the intended endpoint should prompt reassessment of diagnosis, adherence, exposure, comorbidity, and phenotype before indefinite escalation.

Counseling is part of treatment. Patients should understand which exposure truly requires avoidance, what can be safely reintroduced, when to use emergency medication, how to recognize recurrence, and whether family members or healthcare systems need special documentation. Overly broad avoidance can create nutritional, antimicrobial, occupational, and quality-of-life harms just as under-recognition can create medical risk.
Special populations and comorbidities change both risk and test interpretation. Uncontrolled asthma increases the danger of food or venom reactions and can make challenge or immunotherapy unsafe until stabilized. Pregnancy, beta-blocker use, cardiovascular disease, immune-suppressive medications, and mast-cell disorders may change reaction severity or rescue planning. In suspected immune deficiency, protein loss, hematologic malignancy, immunosuppressive drugs, HIV, and other secondary causes must be excluded before assigning a primary immune diagnosis.

Documentation should be precise because allergy labels propagate across healthcare systems. Record the suspected agent, formulation if relevant, dose/route, latency, objective symptoms, treatment required, time to resolution, and whether the reaction represents immediate allergy, delayed hypersensitivity, intolerance, or an uncertain historical label. For chronic inflammatory disease, record the phenotype and objective control measure that justified step-up therapy. This level of detail prevents both dangerous re-exposure and unnecessary lifetime avoidance.

Treatment Strategy & Disposition

Treatment for Anaphylaxis: Acute Management should follow the management priority contained in the topic itself: Immediate IM epinephrine in the mid‑anterolateral thigh is first‑line; support airway/breathing/circulation, identify trigger, and arrange observation with autoinjector and action plan at discharge. Relevant therapeutic tools are summarized below, but the clinical indication matters more than the presence of an option in a table. Epinephrine IM has a role in first-line anaphylaxis therapy and is limited by do not substitute antihistamines or steroids. Isotonic crystalloid has a role in hypotension/shock and is limited by reassess frequently. Albuterol has a role in persistent bronchospasm and is limited by adjunct only. H1 antihistamine has a role in skin symptoms after stabilization and is limited by does not reverse life-threatening physiology.

Separate acute rescue from long-term disease control. Anaphylaxis requires immediate epinephrine and supportive resuscitation. Bradykinin-mediated angioedema requires airway-focused care and withdrawal of the culprit pathway rather than assuming histamine-directed drugs will work. Severe cutaneous drug reactions require immediate culprit withdrawal and organ-supportive specialty care. Chronic allergic and inflammatory diseases generally use a step-up approach based on control, exacerbation burden, and treatment toxicity.

Long-term therapy should target a defined phenotype. Antihistamines treat histaminergic urticaria; topical anti-inflammatory therapy treats dermatitis; swallowed steroid/PPI/biologic options address eosinophilic esophagitis; immunoglobulin replacement treats clinically important antibody failure; allergen or venom immunotherapy modifies future reaction risk; asthma biologics should be selected after confirming diagnosis and phenotype. Do not escalate because a biomarker is abnormal in isolation.

Reassessment should be tied to a measurable endpoint such as UCT/UAS7, exacerbation frequency, spirometry, steroid exposure, endoscopic histology, dermatitis severity, infection frequency, or challenge tolerance. Before declaring treatment failure, verify adherence, exposure reduction, inhaler/topical technique, dosing interval, and whether the original mechanism still fits.

Prevention can be as important as medication. Delabel incorrect antibiotic allergies, provide written anaphylaxis plans, teach autoinjector use, document latex precautions, create allergen avoidance lists that are specific rather than indiscriminate, and coordinate vaccines/infection plans for immunodeficiency. Specialty follow-up is required when diagnosis remains uncertain, testing or challenge carries risk, biologic/immunotherapy is being considered, or recurrent severe disease persists.
Long-term plans should minimize treatment toxicity as control improves. Avoid chronic systemic corticosteroids when safer disease-modifying options exist, review the ongoing need for avoidance and rescue medications, and reassess whether biologic or immunotherapy is producing the outcome that justified it. When disease is controlled, simplify the regimen where possible without removing the therapy that prevents severe recurrence.

Epidemiology / Risk Factors

• Allergic and immune-mediated disease is strongly influenced by age, atopic background, medication and occupational exposures, infection history, and comorbid asthma or skin disease.
• Prevalence of sensitization is higher than prevalence of clinically important allergy; epidemiology should guide suspicion but not replace mechanism-specific confirmation.

Investigations

Epinephrine At‑a‑Glance

Pharmacology

Prognosis / Complications

• Prognosis depends on mechanism, severity, comorbid asthma/organ disease, trigger control, and response to appropriate step-up therapy.
• Many chronic allergic conditions can achieve good control, but recurrent steroid exposure, repeated anaphylaxis, organ injury, or infection burden signal inadequate control.
• Accurate delabeling or mechanism definition can improve quality of life and reduce unnecessary avoidance, medication use, and healthcare risk.

Patient Education / Counseling

• Teach the patient which exposure truly requires avoidance and which labels or restrictions may be reconsidered after appropriate testing.
• Provide a written emergency plan and device technique when epinephrine or other rescue therapy is prescribed.
• Explain that positive allergy testing reflects sensitization and must be interpreted with the clinical history.
• For chronic disease, review the control target, step-up criteria, adverse effects, and when specialty reassessment is needed.

Notes

Use the structured sections above as a clinical reference, not as a rigid protocol. Individual management for Anaphylaxis: Acute Management depends on age, pregnancy status when relevant, organ function, comorbidity, anatomy, contraindications, local resources, and patient preferences. Topic-specific branch points: Adult IM → 0.3–0.5 mg (1 mg/mL) lateral thigh; Pediatric IM → 0.01 mg/kg up to 0.3–0.5 mg; Infusion → 1–10 mcg/min titrate to MAP; β‑blocker patient → Add glucagon 1–2 mg IV; Autoinjectors → 0.1/0.15/0.3 mg strengths. If the reaction phenotype and test result conflict, revisit the mechanism before broadening avoidance or escalating long-term therapy.

References

1. AAAAI — Practice Parameters and Guidelines — Link